The five-year survival rate of chronic granulocytic leukemia can be more than 95%. How long you can live cannot be generalized, but needs to be decided according to individual differences and treatment methods. Chronic granulocytic leukemia can be better treated with oral tyrosine kinase inhibitors, such as first-generation imatinib, second-generation nilotinib or dasatinib. Current research suggests that nearly half of patients can discontinue the drug if deep molecular remission is achieved and lasts more than 2 years. If tyrosine kinase inhibitors are used regularly and tested periodically, 82% to 90% of patients can survive long-term. Patients with chronic granulocytic leukemia should standardize the use of medication, inadequate dosage and arbitrary reduction and discontinuation of drugs may affect the efficacy of treatment. Therefore, the rules of drug use should be used in accordance with the doctor’s instructions, and should not reduce or stop the drug on their own. In order to reduce the incidence of chronic granulocytic leukemia, try to avoid contact with toxic and harmful chemicals, stay away from high radiation areas, and also improve immunity through exercise and diet.